Matthew Wakefield, PhDThe Walter & Eliza Hall Institute of Medical Research2020 Rosser Family Pilot Study Award Identifying all mutations in the PARP1 catalytic domain that impact PARP inhibitor action PARP inhibitors are a class of drugs that are becoming a major part of treatment for high grade ovarian cancer. These drugs kill cancer cells by […]
Read More
Young Min Chung, PhDStanford University Targeting Ovarian Cancer with Combination of Olaparib and Trifluoperazine Dr. Chung is developing innovative therapeutic strategies by combining a clinically used small-molecule drug called trifluoperazine (TFP) and a chemical compound named Olaparib, which is an inhibitor of an enzyme called PARP, to suppress advanced ovarian cancer and to overcome PARP […]
Read More
Thuy-Vy Do, PhDFox Chase Cancer Center Preclinical Evaluation of Aurora A Kinase and PARP Inhibitor Combination Therapy Women carrying mutations in the breast-cancer associated 1 or 2 (BRCA1/2) genes are at higher risk for developing epithelial ovarian cancer. BRCA1/2 play critical roles in repairing DNA and helping genes avoid mutation. Interestingly, BRCA1/2 is not functioning […]
Read More
Lilie Lin, MDUniversity of Pennsylvania School of Medicine Pilot study of a novel PARP inhibitor PET tracer in patients with ovarian carcinoma Targeted agents such as poly-ADP ribose polymerase (PARP) inhibitors are actively being tested alone or in combination with chemotherapy or radiotherapy as promising treatments for ovarian cancer. However, not all patients will respond […]
Read More
Denise Connolly, PhDFox Chase Cancer Center2015 Pape Family Pilot Award Sensitizing ovarian cancer to PARP inhibition PARP inhibitors are among the most promising class of targeted therapeutics for the treatment of ovarian cancer. Patients with mutations in BRCA genes and some patients with sporadic cancers are particularly sensitive to this class of drugs, presumably because […]
Read More
Andrew Wilson, PhDVanderbilt University Prognostic Significance of TR3/NR4A1 Expression in Ovarian Cancer A key clinical problem in the management of advanced ovarian cancer is tumor resistance to traditional platinum drugs and to newer drugs that inhibit the PARP protein (PARPi). Dr. Wilson will investigate an innovative approach to improve the effects of platinum drugs and […]
Read More
Alan D’Andrea, MDDana-Farber Cancer Institute Novel mechanisms of PARP-inhibitor resistance in BRCA2-deficient ovarian and breast cancer PARP inhibitors are a promising class of drugs for the treatment of ovarian cancers with defects in the BRCA1 or BRCA2 genes. However, drug resistance to PARP inhibitors poses a significant challenge for clinicians. Dr. D’Andrea’s group has recently […]
Read More
Alvaro Monteiro, Ph.D.H. Lee Moffitt Cancer Center & Research InstituteTampa, FL, United States Project: Tackling PARP inhibitor resistance through functional proteomics Research Areas: Chemotherapy Resistance Summary:There has been significant progress in ovarian cancer treatment especially with the development and approval of PARP inhibitor drugs. Despite this progress, a sizable percentage of patients do not respond or stop […]
Read More